每年2月的最后一天是"国际罕见病日"。在我国，罕见病患者已超2000万，构成了一个不可忽视的群 体。在全球所有已知的罕见病中，存在有效治疗手段的仅约5%。而诊疗过程中，42%的患者经历过误 诊，平均确诊时间为4.26年，这更加重了患者的诊疗负担。 研究显示，罕见病带来的疾病负担远高于常见疾病，因病致贫率在我国超过了35%。同时，对患者家庭 和社会而言，罕见病导致的肢体残疾、心理折磨、自理能力丧失，阻碍了患者回归社会，这也导致整个 家庭需要承担无休止的照料责任与精神压力。医疗卫生体系亟待填补这一保障缺口。 为此，世界卫生组织于2025年第一次将罕见病列为全球卫生公平和包容的优先事项，敦促各成员国制定 国家罕见病健康计划，内容包括提升诊断水平、提供可负担的治疗，以及出台更多支持研究和创新的政 策。这也为中国罕见病诊疗保障体系的完善指明了方向。 近年来，我国在罕见病领域的进步有目共睹。《2026罕见病行业趋势观察报告》显示，2025年中国罕见 病治理正经历一场深刻的系统性变革，各主要领域均有突破。截至 2025年底，已有71种罕见病的140种 药物纳入医保目录。2025年12月，国家医保局、人力资源社会保障部发布" ...

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. For over a decade, pharmacy benefit managers have been in the hot seat, absorbing the bulk of Washington's bipartisan scrutiny over rising prescription drug costs. Now, the pricing pendulum is swinging back in pharma’s direction. Sweeping reforms in the Consolidated Appropriations Act of 2026, signed into law by President Donald Trump earlier this month, included ch ...

Group 1 - The core objective of Tianhe District is to achieve a GDP growth of over 5% and fixed asset investment growth of over 10% by 2026, with a total investment exceeding 800 billion yuan in over 500 projects this year [1][2] - The district aims to strengthen the modern service industry, focusing on high-end production services and enhancing the role of licensed financial institutions, which have surpassed 310 in number [1] - Tianhe will promote the transformation and upgrading of modern commerce, particularly in sectors like chemicals, automotive, and pharmaceuticals, while embedding high-end professional services into the manufacturing chain [1] Group 2 - The district plans to enhance the quality and diversity of life services, aiming to elevate the Tianhe Road-Zhujiang New Town commercial area to a trillion-level market, with over 300 unique consumer events planned [2] - The artificial intelligence industry is targeted to achieve revenue exceeding 62 billion yuan, with a growth rate of over 12% this year, focusing on sectors like AI and robotics, smart connected vehicles, and low-altitude economy [2] - Urban renewal projects will see an investment of 35 billion yuan, with specific initiatives targeting 22 urban villages and 27 renovation projects [2]

封面新闻记者 杨金祝 2月27日，马年新春收假首周，成都高新区召开2026年工作会议。 记者从会上获悉，2025年成都高新区实现地区生产总值3661.5亿元、增长6.1%；全年实现社会消费品零售总额1148.3亿元、增长4.0%；实现固定资产投资 805.5亿元、增长12.5%，其中工业投资450.6亿元、增长59.1%；实现外贸进出口总额5508.0亿元，分别占全省、全市的53.4%和64.8%，成都高新综保区进 出口规模和绩效评估首次位列全国"双第一"。 会议现场 全力拼经济搞建设 现代化产业"百花齐放" 作为成都产业发展主阵地，成都高新区圈链融合多点支撑，现代化产业体系基本成势。 电子信息产业实现规上工业增加值增长10.0%，发挥了工业经济重要支柱作用，全国首条高世代AMOLED生产线正式点亮首款产品。医药健康产业创新前 行，引进世界500强武田制药中国首个数字医疗创新中心、华润医药西部创新中心等项目，揭牌成立成都全球新药发现中心，5种"成都高新造"药品纳入国 家医保目录。 数字经济产业实现核心产业增加值1860.2亿元、增长10.8%，引进总投资30亿元的爱奇艺影视新天地、四川省数据集团总部等项目。《 ...

Eli Lilly and Company (NYSE:LLY) is included among the 14 Best GARP Stocks to Buy According to Analysts. RBC Capital Initiates Eli Lilly (LLY), Cites Long-Term Leadership in Obesity Market On February 25, RBC Capital initiated coverage of Eli Lilly and Company (NYSE:LLY) with an Outperform rating and a $1,250 price target. The firm said Lilly’s obesity franchise is positioned to dominate the market through 2030. The analyst noted that investor sentiment remains broadly positive. At the same time, there “ ...

Teehan and Lee emphasized progress on reimbursement outside bundled surgical payments. The company exceeded its internal goal and ended 2025 with 102 million covered lives with CMS or commercial coverage outside the surgical bundle, citing payers including Aetna, Cigna, TRICARE, and Humana. Teehan added that the figure climbed to about 110 million within the first month of 2026 and said Pacira intends to continue expanding coverage.Chief Commercial Officer Brendan Teehan said expanding patient and provider ...

Dr. Elias Zerhouni, Vice Chairman and President, said the post-transaction remaining BioReference operations represented approximately $300 million in revenue in 2025. He said testing volume in the fourth quarter, excluding the divested oncology assets, grew slightly, and that BioReference reduced its workforce by roughly 29% from the prior year to about 1,400 full-time employees as part of broader operational efficiency initiatives. Management said these changes significantly improved margins and underpin ...

Core Viewpoint - Santhera Pharmaceuticals announces that AGAMREE® (vamorolone) has been proposed for inclusion in the pharmaceutical coverage of the Spanish National Health System, making it eligible for reimbursement [1][2]. Group 1: Product Information - AGAMREE® is approved by the European Commission for treating Duchenne muscular dystrophy (DMD) in patients aged 4 and older [3]. - The drug has been available in Spain through a paid named-patient program since mid-2024 [3]. - AGAMREE is positioned as a dissociative anti-inflammatory drug, offering an alternative to existing corticosteroids, with a mechanism that aims to dissociate efficacy from steroid safety concerns [4]. Group 2: Clinical Data - In the pivotal VISION-DMD study, AGAMREE met the primary endpoint of Time to Stand (TTSTAND) velocity versus placebo (p=0.002) at 24 weeks of treatment, demonstrating a good safety and tolerability profile [5]. - Commonly reported side effects included cushingoid features, vomiting, weight increase, and irritability, generally of mild to moderate severity [5]. - Unlike corticosteroids, AGAMREE shows no restriction of growth and no negative effects on bone metabolism, as indicated by normal serum markers for bone formation and resorption [6]. Group 3: Market Strategy - The company plans to start making AGAMREE available across various regions in Spain from early in the second quarter of 2026, following the acceptance of the draft resolution by the Directorate-General of Pharmacy [2]. - This announcement is seen as a significant milestone in expanding access to AGAMREE for DMD patients in Europe and globally, following commercial launches in Germany, Austria, and the UK [4].

锌作为人体必需的微量元素之一，被称为"生命之花"，参与人体200多种酶的合成与激活，贯穿生长发 育、免疫调节、物质代谢、生殖健康等全部生理过程。世界卫生组织（WHO）1973年已确认锌为人体 必需微量元素并制定膳食标准，锌缺乏可引发生长迟缓、免疫力下降、生殖功能异常等问题。《中国居 民营养与慢性病状况报告（2025年）》显示，我国3岁以下婴幼儿锌缺乏发生率达18.6%，学龄前儿童 锌摄入不足率22.3%，锌缺乏已成为影响居民尤其是儿童生长发育的主要营养问题。 一、核心认知：药字号与食字号的本质区别 药字号与食字号补锌产品并非简单"药品与食品"的差异，在审批、生产、功效、安全等方面存在根本区 别。结合国家药品监督管理局（NMPA）及卫生健康委员会相关规定，明确：对于确诊缺锌或有明确缺 锌风险的人群，药字号产品是临床首选，食字号仅可作为健康人群日常轻微补充，不可替代药字号用于 治疗。 （一）药字号补锌产品（临床首选，疗效确切） 药字号产品（批准文号为"国药准字+字母+8位数字"）属于药品范畴，需经NMPA严苛审批，完成Ⅰ-Ⅲ 期临床试验，证实疗效与安全性后才可上市，核心特点如下： 1. 审批标准：需提交完整临床研 ...

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is one of the best small-cap stocks with huge growth potential. On February 18, Evercore ISI resumed coverage of BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) with a Buy rating and set a price target of $17.00. BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) also received a rating update from Bank of America Securities on January 27, which reaffirmed a Buy rating on the stock with a price target of $15. Cantor Fitzgerald Sees Deal Activity and Pipeline Progress as Key ...